Radiofrequency ablation and bone augmentation plus radiotherapy vs radiotherapy alone for spinal metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, randomized pilot trial at the University of Minnesota randomizes patients 2:1 to receive one session of radiofrequency ablation with bone augmentation plus radiotherapy or radiotherapy alone for metastatic disease of the T5-L5 spine (up to two levels). The study tracks skeletal-related events—including pathologic fracture, spinal cord or nerve root compression, instability, persistent pain, or need for additional local interventions—over 24 months with assessments at 1, 3, 6, 12, and 24 months. Eligibility requires histologically confirmed spinal metastasis with pain or imaging predictors of SRE and adequate organ function. The primary aim is to compare the occurrence of SREs between the combined RFA/BA+RT arm and the RT-only arm in this pilot setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed metastatic T5-L5 disease of the spine (with up to two levels) as detected by any imaging study.
* Have either associated bone pain or cross-sectional imaging characteristics that are predictors of SRE.
* Age 18 years of age or older at the time of consent.
* Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to study enrollment defined as:

  1. absolute neutrophil count (ANC) ≥ 1.5 × 109/L
  2. platelets ≥ 50 × 109/L
  3. hemoglobin ≥ 10 g/dL, independent of transfusion ≤14 days of screening
  4. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); if liver metastases, then ≤ 5 × ULN
  5. total bilirubin ≤ 1.5 × ULN; \< 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome
  6. serum albumin ≥ 30 g/L (3.0 g/dL)
  7. serum creatinine ≤ 1.5 x ULN; OR estimated glomerular filtration rate (GFR) ≥ 45 mL/min using the Cockcroft Gault formula
* Persons of childbearing potential (POCB) or with partners of childbearing potential must be willing to use contraception during study treatment and 6 months after study treatment.
* Persons are considered to be of childbearing potential unless one or the following applies:

  1. Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause
  2. Considered permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy
* Voluntary written consent prior to the performance of any research related activity

Exclusion Criteria:

* Pregnant or breastfeeding.
* Clinical or radiologic evidence of epidural spinal cord compression or radicular pain.
* Prior radiation therapy to the target lesion.
* Candidates for spine stabilization surgery.
* The target lesion(s) is deemed ineligible for RFA/BA (e.g. unstable existing fractures/impending fractures, involvement of the posterior elements, retropulsion, spinal canal narrowing, neuroforaminal narrowing, uncontrolled bleeding diathesis, active infection anywhere in the body, or purely blastic tumor). Note: Mixed lytic/blastic tumors are eligible.
* The target lesion(s) size or location is beyond RFAs ability to safely perform, at the physician's discretion

Where it's running

• University of Minnesota
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Reza Talaie — University of Minnesota
• Study coordinator: Surgery Clinical Trials Office
• Email: surgCTO@umn.edu
• Phone: 612-624-7463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Heart-friendly medicines to protect chest-area cancer patients from radiation damage

  This Phase 2 trial tests whether taking atorvastatin and lisinopril can reduce heart damage in adults with chest-area cancers who receive radiation therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07685938

• Preventing G-CSF bone pain with diosmin-hesperidin and loratadine

  We will test whether diosmin-hesperidin, loratadine, or both can prevent bone pain from G-CSF in adults with leukemia or lymphoma.

  Recruiting Alexandria University · Alexandria · NCT07300735

• Spine tumor registry tracking outcomes after separation surgery and radiation

  This registry will collect information to see what outcomes adults with primary or metastatic spine tumors have after separation surgery followed by radiation.

  Recruiting at 5 sites Ohio State University Comprehensive Cancer Center · Indianapolis, Indiana and 4 other locations · NCT07225491

• Samarium-153 treatment optimized for longer-lasting relief of end-stage cancer bone pain

  This trial will test a samarium-153 radioligand injection to see if it reduces severe bone pain in adults with advanced cancer and painful bone metastases.

  Recruiting at 6 sites Phase 1 Telix Pharmaceuticals (Innovations) Pty Limited · Miami, Florida and 5 other locations · NCT07197645

• Evaluating radiofrequency ablation and stabilization for metastatic spine lesions

  This study is testing if a new treatment that combines radiofrequency ablation and stabilization can help people with certain types of spine tumors feel better by looking at changes in their lesions after treatment.

  Recruiting National and Kapodistrian University of Athens · Athens, Athens · NCT06716294

• Radiation treatment for high-risk spine cancer patients

  This study is testing a new type of radiation treatment for patients with cancer that has spread to the spine to see if it can help manage their condition without needing major surgery.

  Recruiting Phase 2 Stony Brook University · Stony Brook, New York · NCT06165419

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.